Catalent Pharma Solutions plans to more than double its bioreactor capacity, adding a 1,000-liter bioreactor train at its Middleton, WI facility by 2009. The expansion is in response to increased demand for production to support clinical trials. The company has supplied two biopharma companies with GPEx-produced proteins that are currently being used in FDA-approved IND clinical trials.
The GPEx technology is designed to aid in the development of new biopharmaceuticals in a compliant, timely and cost-effective manner. According to the company, the GPEx system produces stable, high-yielding mammalian cell lines for protein production more quickly and efficiently than competing technologies. In addition, GPEx technology has generated more 150 cell lines for production of recombinant proteins and antibodies, one of which is currently being used to manufacture a commercially available biosimilar product.
Magazine
